hAPOC3

品系全名

C57BL/6Smoc-Apoc3em1(hAPOC3)Smoc

目錄號(hào)

NM-HU-225050

品系狀態(tài)

活體

導(dǎo)出PDF

基因信息

基因名
Apoc3

基因曾用名

apo-CIII; apoC-III

NCBI ID

MGI ID

Ensembl ID

Pubmed

人類同源基因

APOC3

品系描述

利用同源重組，將小鼠Apoc3基因進(jìn)行人源化修飾。

驗(yàn)證數(shù)據(jù)

image.png

Fig1. Detection of APOC3 expression in liver by RT-PCR.?

Wild type: only one band at 196 bp with primers F1/R1(mApoc3);?

Homozygous: only one band at 219 bp with primers F2/R2(hAPOC3).?

Abbr. M, DNA marker; HO, homozygous; WT, wild type.

image.png

Fig2. Detection of species-specific APOC3 expression in serum by ELISA.?

Abbr. HO, homozygous; HE, heterozygous; WT, wild type.

image.png

Fig3.?Monitoring of blood lipids levels in hAPOC3 mice (n=3 female and 3 male).?

Abbr. Hom, homozygous; WT, wild type.

image.png

Fig4.?In Vivo Efficacy?of APOC3 RNAi (ARO-APOC3) in hAPOC3 Mice.

hAPOC3 mice (male, 13 weeks old) were randomly divided into two groups(n=5/group). Mice were administered with ARO-APOC3, a nucleic acid drug targeting hAPOC3, synthesized according to the relevant patents. Blood lipids level of hAPOC3 mice before or after dosing were detected. Compared to vehicle, ARO-APOC3 treatment group showed a decrease in TG, T-CHO and LDL-C. Mean ± SEM. t-test, *P < 0.05, ***P < 0.001.

image.png

Fig5.?In Vivo Efficacy?of APOC3 RNAi (ARO-APOC3) in hAPOC3 Mice.

hAPOC3 mice (male, 13 weeks old) were randomly divided into two groups(n=5/group). Mice were administered with ARO-APOC3, a nucleic acid drug targeting hAPOC3, synthesized according to the relevant patents. At day 29 post-dosing, the mice were euthanized, and their livers were collected for the assessment of human APOC3 mRNA expression via qPCR. The results indicated a significant reduction in human APOC3 expression in the ARO-APOC3 treatment group compared to the vehicle control. Mean ± SEM. t-test.

image.png

Fig6.?In Vivo Efficacy?of APOC3 RNAi (ARO-APOC3) in hAPOC3 Mice.?

hAPOC3 mice (male, 13 weeks old) were randomly divided into two groups(n=5/group). Mice were administered with ARO-APOC3, a nucleic acid drug targeting hAPOC3, synthesized according to the relevant patents. Expression level of hAPOC3 before or after dosing at indicated timepoint was detected by ELISA. Compared to vehicle, ARO-APOC3 treatment group showed a significant decrease in the expression of hAPOC3. Mean ± SEM. t-test, ***P < 0.001

你也可能感興趣

Tamoxifen誘導(dǎo)Cre-ERT2小鼠 使用指南

Cre-ERT2在無Tamoxifen誘導(dǎo)的情況下，在細(xì)胞質(zhì)內(nèi)處于無活性狀態(tài)；當(dāng)Tamoxifen誘導(dǎo)后，Tamoxifen的代謝產(chǎn)物4-OHT（雌激素類似物）與ERT結(jié)合，可使Cre-ERT2進(jìn)核發(fā)揮Cre重組酶活性。

查看
【小鼠大學(xué)問】基因工程小鼠的命名規(guī)則

常見的基因工程小鼠可以分為兩種命名方式，包括基因定點(diǎn)修飾的小鼠命名，比如：敲除、敲入、點(diǎn)突變等等，和隨機(jī)轉(zhuǎn)基因的小鼠命名。

查看